Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Id-KLH vaccine + QS-21
- Development stage
- Unknown
- Lead developer
- Agenus
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Id-KLH vaccine + QS-21 is a personalized autologous therapeutic cancer vaccine developed by the National Cancer Institute (NCI) for the treatment of follicular lymphoma. The vaccine is composed of a patient-specific tumor-derived immunoglobulin idiotype (Id) protein, which acts as a unique tumor-associated antigen, chemically conjugated to the carrier protein keyhole limpet hemocyanin (KLH) to enhance its immunogenicity. This conjugate is administered in combination with QS-21, a purified plant-derived saponin that serves as an immunological adjuvant to further stimulate both humoral and cellular immune responses against the malignant B-cells. The treatment protocol typically involves administering the vaccine to patients who have achieved clinical remission or minimal disease status following standard chemotherapy, with the goal of eradicating residual tumor cells and preventing disease recurrence.
- Other names
- autologous tumor-derived immunoglobulin idiotype-KLH vaccineId-KLH VaccineQS-21 (Stimulation-QS-21) Drug
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on Id-KLH vaccine + QS-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Id-KLH vaccine + QS-21.